A Herpes Simplex Virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Zhang, Pengwei ^a   Xie, Lining ^a   Balliet, John W ^b   Casimiro, Danilo R ^b   Yao, Feng ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; GLYCOPROTEIN D; GLYCOPROTEIN D2; HERPES SIMPLEX GLYCOPROTEIN D2 VACCINE; HERPES SIMPLEX VACCINE; NEUTRALIZING ANTIBODY; NONREPLICATING DOMINANT NEGATIVE HSV 2 GLYCOPROTEIN D2 RECOMBINANT VIRAL VACCINE; PHOSPHORYL LIPID A; PLACEBO; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; DNA VACCINE; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GENITAL HERPES; GUINEA PIG MODEL; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PROVOCATION TEST; SPINAL GANGLION; VIRUS NEUTRALIZATION; WILD TYPE; ANIMAL; CHLOROCEBUS AETHIOPS; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; GUINEA PIG; HAMSTER; HERPES GENITALIS; HUMAN; IMMUNOLOGY; TUMOR CELL LINE; VERO CELL LINE;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HUMANS; VACCINES, DNA; VACCINES, SUBUNIT; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 84903643342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101373     Document Type: Article

References (59)

1. Koelle DM, Corey L (2008) Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annu Rev Med 59: 381-395. (Pubitemid 351287944)
2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, et al. (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Jama 296: 964-973. (Pubitemid 44285373)
3. Schillinger JA, Xu F, Sternberg MR, Armstrong GL, Lee FK, et al. (2004) National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 31: 753-760. (Pubitemid 39557424)
4. Whitley RJ (2001) Herpes Simplex Viruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 2461- 2509.
5. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 20: 73-83. (Pubitemid 41818117)
6. Stanberry LR (2004) Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl 3: 161A-169A.
7. Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L (2012) Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol 2012: 187585.
8. Yao F, Eriksson E (1999) A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther 10: 1811-1818. (Pubitemid 29357687)
9. Yao F, Eriksson E (2002) Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res 53: 127-133. (Pubitemid 34062832)
10. Lu Z, Brans R, Akhrameyeva NV, Murakami N, Xu X, et al. (2009) High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol 129: 1174- 1184.
11. Brans R, Akhrameyeva NV, Yao F (2009) Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol 129: 2470-2479.
12. Brans R, Eriksson E, Yao F (2008) Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol 128: 2825-2832.
13. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F (2011) Development of a glycoprotein D-expressing dominant-negative and replica-tion- defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 85: 5036-5047.
14. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC Jr (1982) Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 146: 397-404. (Pubitemid 12031217)
15. Stanberry LR, Kern ER, Richards JT, Overall JC Jr (1985) Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24: 226-231. (Pubitemid 16210922)
16. Yao F, Schaffer PA (1995) An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol 69: 6249-6258.
17. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, et al. (1998) Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 9: 1939-1950. (Pubitemid 28439099)
18. Yao F, Eriksson E (1999) A novel tetracycline-inducible viral replication switch. Hum Gene Ther 10: 419-427. (Pubitemid 29097320)
19. Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, et al. (2014) Protection Provided by a Herpes Simplex Virus 2 (HSV-2) Glycoprotein C and D Subunit Antigen Vaccine against Genital HSV-2 Infection in HSV-1-Seropositive Guinea Pigs. J Virol 88: 2000-2010.
20. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117-2123. (Pubitemid 41779210)
21. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, et al. (2009) Protection from herpes simplex virus (HSV)-2 infection with replication- defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200: 1088-1095.
22. Brans R, Yao F (2010) Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 10: 163.
23. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661. (Pubitemid 35340783)
24. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43.
25. Augustinova H, Hoeller D, Yao F (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78: 5756-5765. (Pubitemid 38661663)
26. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, et al. (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79: 410-418. (Pubitemid 39648394)
27. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, et al. (2011) A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6: e17748.
28. Johnston C, Koelle DM, Wald A (2011) HSV-2: in pursuit of a vaccine. J Clin Invest 121: 4600-4609.
29. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 86: 4586-4598.
30. Halford WP, Geltz J, Gershburg E (2013) Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 8: e65523.
31. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, et al. (2003) Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187: 542-549. (Pubitemid 36250017)
32. Blaney JE, Jr., Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, et al. (1998) Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 72: 9567-9574. (Pubitemid 28520820)
33. Orr MT, Orgun NN, Wilson CB, Way SS (2007) Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178: 4731- 4735.
34. DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, et al. (1998) Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 101: 1500-1508.
35. van Lint A, Ayers M, Brooks AG, Coles RM, Heath WR, et al. (2004) Herpes simplex virus-specific CD8+ T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J Immunol 172: 392-397. (Pubitemid 38020493)
36. Wakim LM, Jones CM, Gebhardt T, Preston CM, Carbone FR (2008) CD8(+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection. Immunol Cell Biol 86: 666-675.
37. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, et al. (2007) Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204: 595-603. (Pubitemid 46457082)
38. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, et al. (2008) Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322: 268-271.
39. Milligan GN, Bernstein DI, Bourne N (1998) T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 160: 6093-6100. (Pubitemid 28298073)
40. Cohen J (2010) Immunology. Painful failure of promising genital herpes vaccine. Science 330: 304.
41. Bernstein DI, Earwood JD, Bravo FJ, Cohen GH, Eisenberg RJ, et al. (2011) Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 29: 2071-2078.
42. Dudek T, Knipe DM (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230-239. (Pubitemid 41814465)
43. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, et al. (2006) Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80: 5509-5515.
44. Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, et al. (2000) Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 164: 5167-5176. (Pubitemid 30305192)
45. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, et al. (2010) Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 184: 3250-3259.
46. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, et al. (1994) A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77: 525-535.
47. Hill A, Jugovic P, York I, Russ G, Bennink J, et al. (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415.
48. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, et al. (1995) A viral inhibitor of peptide transporters for antigen presentation. Nature 375: 415-418.
49. Dubin G, Socolof E, Frank I, Friedman HM (1991) Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 65: 7046-7050.
50. Sievers E, Neumann J, Raftery M, SchOnrich G, Eis-Hubinger AM, et al. (2002) Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules. Immunology 107: 129-135.
51. He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, et al. (1997) Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 71: 6049-6054. (Pubitemid 27304944)
52. Eidson KM, Hobbs WE, Manning BJ, Carlson P, DeLuca NA (2002) Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J Virol 76: 2180-2191. (Pubitemid 34150685)
53. Mossman KL, Smiley JR (2002) Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol 76: 1995-1998. (Pubitemid 34094647)
54. Daubeuf S, Singh D, Tan Y, Liu H, Federoff HJ, et al. (2009) HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood 113: 3264- 3275.
55. Paul WE (2011) Bridging innate and adaptive immunity. Cell 147: 1212-1215.
56. Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, et al. (2011) A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 29: 1090-1098.
57. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X (2011) Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29: 158-163.
58. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158. (Pubitemid 43361590)
59. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM (2006) Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 80: 5283-5291.